We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our
Privacy Policy
.
Yes, I accept
Menu
Corporate Members
E-Library
Twitter
Linked In
Facebook
Instagram
Join
MyESTRO
Search Opener
Search for:
About ESTRO
Membership
School
Workshops
Congresses
Science
Education
Advocacy
Corporate Members
E-Library
Home
Programme
Clinical track: Lower GI (colon, rectum,...
No date
Session
Clinical track: Lower GI (colon, rectum, anus)
Session Code:
9306
Session Type:
Poster
Track:
Clinical
Add to
My Programme
00:00 - 00:00
Short Course Radiationtherapy chemotherapy and delayed surgery in locally advanced rectal carcinoma
Presentation Number:
PO-1088
00:00 - 00:00
Efficacy and tolerance of VMAT-SIB intensified neoadjuvant chemoradiation in rectal cancer patients
Presentation Number:
PO-1083
00:00 - 00:00
Systematic review of colorectal/anal cancer guidelines: managing long-term symptoms and functioning
Presentation Number:
PO-1079
00:00 - 00:00
Major and complete response after neoadjuvant treatment in rectal cancer: a retrospective analysis
Presentation Number:
PO-1089
00:00 - 00:00
C-reactive protein-to-albumin ratio is a predictive marker for anal squamous cell carcinoma
Presentation Number:
PO-1080
00:00 - 00:00
Patterns of care analysis of treatment of anal squamous cell carcinoma in German speaking countries
Presentation Number:
PO-1081
00:00 - 00:00
Stereotactic pelvic reirradiation for locoregional cancer relapse
Presentation Number:
PO-1084
00:00 - 00:00
Simultaneous integrated boost and volumetric modulated arc radiotherapy in rectal cancer
Presentation Number:
PO-1087
00:00 - 00:00
Predicting the consensus molecular subtypes of colorectal cancer by weakly supervised deep learning
Presentation Number:
PO-1085
00:00 - 00:00
Identification of Cell-Free DNA profile in oligometastatic colorectal cancer
Presentation Number:
PO-1082
00:00 - 00:00
Innovative technologies in treatment of patients with squamous cancer of the anal canal
Presentation Number:
PO-1086
00:00 - 00:00
Dose-volume analysis and sphincter-related toxicity of radiation therapy for rectal cancer
Presentation Number:
PO-1102
00:00 - 00:00
THE ENERGY METABOLISM CHANGES IN RECTAL CANCER PATIENTS AFTER NEOADJUVANT RADIOCHEMOTHERAPY
Presentation Number:
PO-1103
00:00 - 00:00
EFFECT OF NEOADJUVANT RADIOCHEMOTHERAPY ON ACTIVITY OF PARAOXONASE -1 IN RECTAL CANCER PATIENTS
Presentation Number:
PO-1104
00:00 - 00:00
Interstitial PDR brachytherapy for the treatment of squamous cell anal carcinoma
Presentation Number:
PO-1105
00:00 - 00:00
Dose intensification in locally advanced rectal cancer: a prospective observational study
Presentation Number:
PO-1106
00:00 - 00:00
Impact of fractionation on the treatment of squamous cell anal cancer: a dual-institution experience
Presentation Number:
PO-1107
00:00 - 00:00
SCRT and chemotherapy vs LCRT for unresectable rectal cancers. A propensity matched-pair analysis
Presentation Number:
PO-1108
00:00 - 00:00
Radiotherapy toxicity in older patients with rectal cancer
Presentation Number:
PO-1109
00:00 - 00:00
Bladder dose constraints for conformal radiotherapy in rectal cancer: adaptation to prescribed dose
Presentation Number:
PO-1110
00:00 - 00:00
Pathological lymph node staging for intermediate-risk rectal cancer patients
Presentation Number:
PO-1111
00:00 - 00:00
Total neoadjuvant therapy in high risk rectal cancer: a feasibility pilot study
Presentation Number:
PO-1112
00:00 - 00:00
Intensified IMRT-SIB and capecitabine-based chemotherapy in anal cancer:an institutional experience
Presentation Number:
PO-1113
00:00 - 00:00
Patient reported toxicity of short course radiotherapy with interval to surgery for rectal cancer.
Presentation Number:
PO-1114
00:00 - 00:00
WHAT’S THE ROLE OF TUMOR REGRESSION GRADE (TRG) IN RECTAL CANCER: AN ISTUTUTIONAL EXPERIENCE
Presentation Number:
PO-1115
00:00 - 00:00
Quality of life among men who have sex with other men treated for anal cancer: Impact of HIV status
Presentation Number:
PO-1090
00:00 - 00:00
Quality of life and sexual function of men who have sex with other men treated for anal cancer
Presentation Number:
PO-1091
00:00 - 00:00
Clinical results of particle therapy in patients with postoperative recurrence of rectal cancer
Presentation Number:
PO-1092
00:00 - 00:00
Defecography for sphincter evaluation in rectal cancer patients irradiated with dose intensification
Presentation Number:
PO-1093
00:00 - 00:00
Pathological complete response and outcomes in rectal cancer patients with treatment intensification
Presentation Number:
PO-1094
00:00 - 00:00
Does CEA decrease after radical treatment of unresectable rectal cancer predicts the outcome?
Presentation Number:
PO-1095
00:00 - 00:00
Who needs postoperative CCRT in patients with pT3N0 rectal cancer with negative resection margin?
Presentation Number:
PO-1097
00:00 - 00:00
Dosimetric correlation of acute urinary toxicity in patients with rectal cancer treated with IMRT
Presentation Number:
PO-1098
00:00 - 00:00
Response prediction by daily fractional MRI during neoadjuvant radiochemotherapy in rectal cancer
Presentation Number:
PO-1099
00:00 - 00:00
Impact of neutrophil-lymphocyte ratio on the response of chemoradiation therapy of rectal cancer
Presentation Number:
PO-1100
00:00 - 00:00
Intensity-modulated radiotherapy treatment of anal cancer: single-institution outcomes
Presentation Number:
PO-1101
E-Mail Address
Please enter a user name
Password
Cancel
Forgotten Password
Create MyESTRO Account
i
Please log in to add this session to your programme.